Literature DB >> 25821006

Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study.

Irene-Ariadne Kechagia1, Aristides Dokoumetzidis.   

Abstract

A preliminary population pharmacokinetic (PopPK) model of valacyclovir in children was developed from non-compartmental analysis (NCA) parameter values from literature, including several age groups, combined with Bayesian priors from a PopPK model of acyclovir, the active metabolite of valacyclovir, from literature too. Also a simulation study was carried out to evaluate the performance of various modelling choices related to the estimation of model parameters from NCA parameters originating from sparse PK studies. Assuming a one-compartment model with first order absorption, a mixed effects, meta-analysis approach was utilized which allows accounting the random intergroup variability, the detection of covariates and the application of informative Bayesian priors on the parameters. The conclusions from the simulation study calculating bias and precision for various cases, were that a model which takes explicitly into account the sampling schedule, performs better than a model using the theoretical expressions of calculating the NCA parameters. Also by using the geometric rather than the arithmetic means of NCA parameters, less biased results are obtained. These findings guided the choices for the valacyclovir model, for which informative priors from a PopPK model of acyclovir were applied for some of the parameters, in order to include a richer covariate model for clearance, not supported by the NCA dataset and a value for bioavailability. This preliminary valacyclovir model can be used in simulations to provide dosage recommendations for children of various ages and to help design more efficiently prospective clinical trials.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25821006     DOI: 10.1007/s10928-015-9412-6

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  10 in total

1.  Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel.

Authors:  Chantaratsamon Dansirikul; Malcolm Choi; Stephen B Duffull
Journal:  Comput Biol Med       Date:  2005-06       Impact factor: 4.589

Review 2.  Reference intervals for serum creatinine concentrations: assessment of available data for global application.

Authors:  Ferruccio Ceriotti; James C Boyd; Gerhard Klein; Joseph Henny; Josep Queraltó; Veli Kairisto; Mauro Panteghini
Journal:  Clin Chem       Date:  2008-01-17       Impact factor: 8.327

3.  Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.

Authors:  Efthymios Manolis; Gérard Pons
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

4.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

5.  Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.

Authors:  M Tod; F Lokiec; R Bidault; F De Bony; O Petitjean; Y Aujard
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.

Authors:  David W Kimberlin; Richard F Jacobs; Stephen Weller; Jan-Stefan van der Walt; Catherine K Heitman; Choy Y Man; John S Bradley
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

7.  Valacyclovir and acyclovir pharmacokinetics in immunocompromised children.

Authors:  Lisa Bomgaars; Patrick Thompson; Stacey Berg; Baruti Serabe; Alek Aleksic; Susan Blaney
Journal:  Pediatr Blood Cancer       Date:  2008-10       Impact factor: 3.167

8.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.

Authors:  G B Haycock; G J Schwartz; D H Wisotsky
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

9.  Non-compartment model to compartment model pharmacokinetics transformation meta-analysis--a multivariate nonlinear mixed model.

Authors:  Zhiping Wang; Seongho Kim; Sara K Quinney; Jihao Zhou; Lang Li
Journal:  BMC Syst Biol       Date:  2010-05-28

10.  Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir.

Authors:  L Zeng; C E Nath; E Y L Blair; P J Shaw; K Stephen; J W Earl; J C Coakley; A J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

  10 in total
  1 in total

1.  The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors.

Authors:  Paweł Wiczling; Alicja Bartkowska-Śniatkowska; Oliwia Szerkus; Danuta Siluk; Jowita Rosada-Kurasińska; Justyna Warzybok; Agnieszka Borsuk; Roman Kaliszan; Edmund Grześkowiak; Agnieszka Bienert
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-24       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.